Pembrolizumab plus Chemotherapy in Lung Cancer
- 13 September 2018
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 379 (11) , e18
Abstract
In the KEYNOTE-189 trial, Gandhi et al. (May 31 issue)1 compared pembrolizumab plus chemotherapy with chemotherapy alone in patients with untreated metastasic non–small-cell lung cancer. They concluded that patients with a tumor proportion score of 50% or more for programmed death ligand 1 (PD-L1) showed a greater benefit with the combination regimen.Keywords
This publication has 13 references indexed in Scilit:
- Hazards of Hazard Ratios — Deviations from Model Assumptions in ImmunotherapyNew England Journal of Medicine, 2018
- Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard RatioJAMA Oncology, 2017
- Evaluation of Evidence of Statistical Support and Corroboration of Subgroup Claims in Randomized Clinical TrialsJAMA Internal Medicine, 2017
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung CancerNew England Journal of Medicine, 2016
- PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel + Carboplatin + Bevacizumab Followed by Maintenance Bevacizumab in Patients ith Advanced Nonsquamous Non–Small-Cell Lung CancerJournal of Thoracic Oncology, 2015
- Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival AnalysisJournal of Clinical Oncology, 2014
- PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2013
- Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2008
- The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trialsJournal of Clinical Epidemiology, 1997
- Statistics Notes: Interaction 1: heterogeneity of effectsBMJ, 1996